Equities Analysts Offer Predictions for GPCR FY2025 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $1.94 per share for the year, down from their previous estimate of $2.04. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share.

Several other research firms also recently issued reports on GPCR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Morgan Stanley started coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. JMP Securities cut their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Finally, HC Wainwright began coverage on Structure Therapeutics in a research note on Wednesday. They set a “buy” rating and a $80.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $85.67.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $33.35 on Thursday. The firm has a market capitalization of $1.91 billion, a P/E ratio of -45.07 and a beta of -3.41. Structure Therapeutics has a one year low of $26.61 and a one year high of $62.85. The company’s fifty day moving average is $37.29 and its two-hundred day moving average is $39.30.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can acquired a new stake in Structure Therapeutics during the 2nd quarter worth approximately $1,064,000. Lighthouse Investment Partners LLC acquired a new stake in Structure Therapeutics in the second quarter valued at approximately $1,178,000. Vestal Point Capital LP grew its position in Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after acquiring an additional 590,000 shares in the last quarter. abrdn plc grew its position in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after acquiring an additional 123,789 shares in the last quarter. Finally, Bellevue Group AG grew its position in Structure Therapeutics by 13.0% in the third quarter. Bellevue Group AG now owns 629,758 shares of the company’s stock valued at $27,640,000 after acquiring an additional 72,437 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.